Editas Medicine Inc (FRA:8EM)
€ 1.262 0 (0%) Market Cap: 98.93 Mil Enterprise Value: -118.33 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 47/100

Q2 2020 Editas Medicine Inc Earnings Call Transcript

Aug 06, 2020 / 09:00PM GMT
Release Date Price: €31.1 (+15.70%)
Operator

Good afternoon, and welcome to Editas Medicine's Second Quarter 2020 Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Mark Mullikin, Vice President of Finance and Investor Relations at Editas Medicine.

Mark J. Mullikin
Editas Medicine, Inc. - Senior Director of Finance & IR

Thank you, operator. Good afternoon, everyone, and welcome to our second quarter 2020 conference call. Earlier this afternoon, we issued 2 press releases. The first press release announces the termination of our agreement with Allergan for the development of ocular medicines, returning full control of these programs to Editas Medicine. The second press release provides our financial results and corporate updates for the second quarter of 2020.

A replay of today's call will be available on the Investors section of our website approximately 2 hours after its completion. After our prepared remarks, we will open the call for Q&A.

As a reminder, various

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot